Clinical Scorecard: The role of social vulnerability index in survival outcomes after autologous stem cell transplantation for multiple myeloma

At a Glance

Key Highlights

• ASCT remains standard of care for eligible MM patients and improves progression-free survival compared to chemotherapy alone
• Social Vulnerability Index (SVI), a composite of 16 social factors grouped into four themes, measures community social vulnerability and may impact post-ASCT outcomes
• This study uniquely evaluates the impact of local-level social vulnerability on survival outcomes after MM ASCT

Guideline-Based Recommendations

Diagnosis

• Use Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART) 3.0 criteria for disease risk stratification
• Apply International Myeloma Working Group (IMWG) Uniform Response Criteria to assess disease progression and response

Management

• Administer high-dose chemotherapy followed by ASCT for eligible MM patients
• Consider maintenance therapy post-ASCT to further improve progression-free survival

Monitoring & Follow-up

• Follow patients from diagnosis to up to 5 years post-transplant
• Monitor disease progression using serum and urine M-component levels, free light chain differences, bone marrow plasma cell percentage, imaging for bone lesions, and calcium levels

Risks

• Recognize that patients residing in areas with higher SVI may have worse survival outcomes post-ASCT
• Consider social determinants of health as potential risk factors influencing access to transplant and survival

Patient & Prescribing Data

Multiple myeloma patients undergoing ASCT in Virginia with documented ZIP codes and social vulnerability data

Patients from high SVI areas may experience disparities in transplant access and survival, highlighting the need for tailored supportive care and resource allocation

Clinical Best Practices

• Incorporate assessment of social vulnerability using CDC SVI to identify patients at higher risk of poor outcomes
• Use standardized criteria (mSMART 3.0 and IMWG) for risk stratification and response evaluation
• Ensure comprehensive data collection including demographic, clinical, and social factors to guide personalized care
• Recognize the influence of socioeconomic and community factors on transplant outcomes and address barriers accordingly

References

• CDC Social Vulnerability Index (SVI)
• International Myeloma Working Group Uniform Response Criteria
• Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART) 3.0